Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease - Takeaways - MDSpire

Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease

  • By

  • Tommaso Lorenzo Parigi

  • Luca Massimino

  • Alfredo Carini

  • Roberto Gabbiadini

  • Peter Bertoli

  • Mariangela Allocca

  • Cristina Bezzio

  • Arianna Dal Buono

  • Ferdinando D’Amico

  • Federica Furfaro

  • Laura Loy

  • Alessandra Zilli

  • Federica Ungaro

  • Vipul Jairath

  • Laurent Peyrin-Biroulet

  • Alessandro Armuzzi

  • Silvio Danese

  • September 12, 2024

  • 0 min

Share

  • 1

    Approximately 24.8% of IBD patients treated with biologics in Italy met at least one criterion for difficult-to-treat inflammatory bowel disease (DTT-IBD).

  • 2

    In ulcerative colitis, left-sided and extended colitis significantly increased the risk of DTT-IBD compared to proctitis.

  • 3

    Crohn's disease patients with multiple localizations, stricturing, penetrating behaviors, and perianal disease were at higher risk for DTT-IBD.

  • 4

    Delayed initiation of advanced treatment was associated with increased risk of DTT in Crohn's disease but was protective in ulcerative colitis.

  • 5

    Symptomatic, biochemical, and endoscopic remission rates were significantly lower in DTT-IBD patients compared to non-DTT-IBD patients.

Original Source(s)

Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease

  • by Tommaso Lorenzo Parigi, Luca Massimino, Alfredo Carini, Roberto Gabbiadini, Peter Bertoli, Mariangela Allocca, Cristina Bezzio, Arianna Dal Buono, Ferdinando D’Amico, Federica Furfaro, Laura Loy, Alessandra Zilli, Federica Ungaro, Vipul Jairath, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Silvio Danese

  • September 12, 2024

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease